Related Experiment Video
Updated: Apr 21, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Interruption of macrophage-derived IL-27(p28) production by IL-10 during sepsis requires STAT3 but not SOCS3
Markus Bosmann1, Norman F Russkamp2, Birgit Strobl3
1Center for Thrombosis and Hemostasis, University Medical Center Mainz, 55131 Mainz, Germany; Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, 55131 Mainz, Germany; markus.bosmann@unimedizin-mainz.de.
Abstract:
Severe sepsis and septic shock are leading causes of morbidity and mortality worldwide. Infection-associated inflammation promotes the development and progression of adverse outcomes in sepsis. The effects of heterodimeric IL-27 (p28/EBI3) have been implicated in the natural course of sepsis, whereas the molecular mechanisms underlying the regulation of gene expression and release of IL-27 in sepsis are poorly understood. We studied the events regulating the p28 subunit of IL-27 in endotoxic shock and polymicrobial sepsis following cecal ligation and puncture. Neutralizing Abs to IL-27(p28) improved survival rates, restricted cytokine release, and reduced bacterial burden in C57BL/6 mice during sepsis. Genetic disruption of IL-27 signaling enhanced the respiratory burst of macrophages. Experiments using splenectomized mice or treatment with clodronate liposomes suggested that macrophages in the spleen may be a significant source of IL-27(p28) during sepsis. In cultures of TLR4-activated macrophages, the frequency of F4/80(+)CD11b(+)IL-27(p28)(+) cells was reduced by the addition of IL-10. IL-10 antagonized both MyD88-dependent and TRIF-dependent release of IL-27(p28). Genetic deletion of STAT3 in Tie2-Cre/STAT3flox macrophages completely interrupted the inhibition of IL-27(p28) by IL-10 after TLR4 activation. In contrast, IL-10 remained fully active to suppress IL-27(p28) with deletion of SOCS3 in Tie2-Cre/SOCS3flox macrophages. Blockade of IL-10R by Ab or genetic deficiency of IL-10 resulted in 3-5-fold higher concentrations of IL-27(p28) in endotoxic shock and polymicrobial sepsis. Our studies identify IL-10 as a critical suppressing factor for IL-27(p28) production during infection-associated inflammation. These findings may be helpful for a beneficial manipulation of adverse IL-27(p28) release during sepsis.
Insights
Interleukin-10 (IL-10) suppresses the release of Interleukin-27 (IL-27) during sepsis. This finding offers a potential therapeutic target for managing sepsis-induced inflammation and improving patient outcomes.
Area of Science:
- Immunology
- Molecular Biology
- Pathophysiology
Background:
- Severe sepsis and septic shock are major global health threats, driven by infection-associated inflammation.
- The role of Interleukin-27 (IL-27) in sepsis is recognized, but its precise regulation remains unclear.
- Understanding IL-27's molecular control is crucial for developing targeted sepsis therapies.
Purpose of the Study:
- To investigate the regulatory mechanisms controlling the expression and release of IL-27(p28) during sepsis.
- To elucidate the role of Interleukin-10 (IL-10) in modulating IL-27 production in sepsis models.
- To identify potential therapeutic strategies targeting IL-27 in sepsis.
Main Methods:
- Utilized mouse models of endotoxic shock and polymicrobial sepsis (cecal ligation and puncture).
- Employed neutralizing antibodies against IL-27(p28) and genetic manipulation (gene deletion of STAT3, SOCS3, IL-10).
- Analyzed macrophage activation, cytokine release, bacterial burden, and survival rates.
Main Results:
- Neutralizing IL-27(p28) improved survival, reduced cytokine release, and decreased bacterial load in septic mice.
- IL-10 significantly inhibited TLR4-induced IL-27(p28) release from macrophages, acting through STAT3-dependent pathways.
- Genetic deficiency or blockade of IL-10 led to a marked increase in IL-27(p28) levels during sepsis.
Conclusions:
- IL-10 is identified as a key negative regulator of IL-27(p28) production in the context of infection-induced inflammation.
- Targeting the IL-10/IL-27 axis presents a promising avenue for therapeutic intervention in sepsis.
- Further research into modulating IL-27 release could lead to improved sepsis management.

